CV Sciences (CVSI) Common Equity (2010 - 2026)

CV Sciences has disclosed Common Equity across 17 years of filings, most recently posting $1.5 million for Q1 2026.

• Common Equity for Q1 2026 came in at $1.5 million, down 20.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 million (down 20.82% YoY), and the FY2025 annual result was $1.5 million, down 18.22% from the prior year.
• Common Equity came in at $1.5 million for Q1 2026 at CV Sciences, up from $1.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $5.0 million in Q1 2023 to a low of -$777000.0 in Q4 2022.
• The 5-year median for Common Equity is $1.9 million (2025), against an average of $2.3 million.
• Across the five-year window, Common Equity tumbled 121.93% in 2022 and soared 473.62% in 2023, its largest moves.
• CV Sciences' Common Equity stood at -$777000.0 in 2022, then jumped by 473.62% to $2.9 million in 2023, then tumbled by 38.17% to $1.8 million in 2024, then decreased by 18.22% to $1.5 million in 2025, then grew by 2.04% to $1.5 million in 2026.
• The last three Common Equity figures came in at $1.5 million (Q1 2026), $1.5 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.